ImmuCell Corporation Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
ImmuCell Corporation (ICCC) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.27% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2023-03-29
- ImmuCell Corporation effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.27%, a 95.62% decline from fiscal 2021.
- ImmuCell Corporation effective income tax rate reconciliation, other adjustments, percent for fiscal 2021 was 6.16%, a 287.42% increase from fiscal 2020.
- ImmuCell Corporation effective income tax rate reconciliation, other adjustments, percent for fiscal 2020 was 1.59%, a 103.85% increase from fiscal 2019.
- ImmuCell Corporation effective income tax rate reconciliation, other adjustments, percent for fiscal 2019 was 0.78%, a 44.44% increase from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2022-12-31 | 0.27% 10-K · filed 2023-03-29 |
| 2021-12-31 | 6.16% 10-K · filed 2023-03-29 |
| 2020-12-31 | 1.59% 10-K · filed 2022-03-30 |
| 2019-12-31 | 0.78% 10-K · filed 2020-03-27 |
| 2018-12-31 | 0.54% 10-K · filed 2020-03-27 |
| 2017-12-31 | 0.40% 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |